Pfizer COVID-19 Vaccine Over 90% Effective
The manufacturer announced the effectiveness of the vaccine. The third phase of vaccine trials began in July and will end in mid-November.
The coronavirus vaccine from Pfizer and BioNTech has shown more than 90% effectiveness in trials. This was reported by the press service of the American company on Monday, November 9.
“A potential candidate for vaccine status has shown its effectiveness in preventing COVID-19 infection by more than 90%,” the statement said.
“Today is a wonderful day for science and humanity. The first part of the results from our third phase of clinical trials of the COVID-19 vaccine provides initial evidence that our drug can prevent coronavirus infections, ”said CEO Albert Burla.
In turn, US President Donald Trump called these results “great news.”
“Stock markets are going up, a vaccine is coming soon. It is reported to be 90% effective. What great news, “Trump wrote on Twitter.
Note that the third phase of trials started on July 27, it was attended by 43 thousand people, almost 40 thousand of whom have received the second dose of the potential vaccine to date.
Now the companies will collect information and data on vaccine safety until mid-November, then all information will be transferred to the US Food and Drug Administration.
If the American regulator urgently approves the vaccine, the first doses of it will be available to doctors by the end of this year.
Recall that earlier Argentina bought 22 million doses of coronavirus vaccine from AstraZeneca. Argentina will receive the vaccine in the first half of 2021 if trials are successful.
It was also reported that the German vaccine will be ready for the final phase of trials by the end of the year. Scientists call intermediate research results “very encouraging.” In the last phase of the test, up to 30 thousand volunteers will take part.